Keros Therapeutics (KROS) News Today → Trump’s Gift Could Unleash $51 Billion in New Wealth (From Wealthpin Pro) (Ad) Free KROS Stock Alerts $46.87 +0.56 (+1.21%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 1 at 3:42 AM | americanbankingnews.comKeros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Rating of "Buy" from AnalystsJune 1 at 3:39 AM | marketbeat.comKeros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Recommendation of "Buy" by AnalystsKeros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) has been given a consensus recommendation of "Buy" by the seven research firms that are currently covering the firm, Marketbeat reports. Seven investment analysts have rated the stock with a buy rating. The average 1-year target price amongMay 28, 2024 | globenewswire.comKeros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of DirectorsMay 27, 2024 | marketbeat.comFranklin Resources Inc. Grows Position in Keros Therapeutics, Inc. (NASDAQ:KROS)Franklin Resources Inc. lifted its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 47.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 699,425 shares of the company's stock afterMay 21, 2024 | investing.comKeros Therapeutics Inc (KROS)May 14, 2024 | globenewswire.comKeros Therapeutics to Present at the 29th Annual Congress of the European Hematology AssociationMay 12, 2024 | marketbeat.comRussell Investments Group Ltd. Buys 18,682 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)Russell Investments Group Ltd. grew its stake in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 24.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 94,557 shares of the company's stock after purchasingMay 10, 2024 | finance.yahoo.comKeros Therapeutics Reports Widening Losses in Q1 2024, Despite Progress in Clinical TrialsMay 9, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Keros Therapeutics as KER-050 Advances Towards Phase 3 for MDS TreatmentMay 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Keros Therapeutics: Promising Pipeline and Strong Financial HealthMay 9, 2024 | marketbeat.comKeros Therapeutics (NASDAQ:KROS) Posts Quarterly Earnings Results, Beats Expectations By $0.12 EPSKeros Therapeutics (NASDAQ:KROS - Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($1.21) earnings per share for the quarter, beating analysts' consensus estimates of ($1.33) by $0.12. The firm had revenue of $0.08 million for the quarter. The business's quarterly revenue was down 97.3% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.26) EPS.May 9, 2024 | marketbeat.comKeros Therapeutics (NASDAQ:KROS) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $100.00 price target on shares of Keros Therapeutics in a research note on Thursday.May 8, 2024 | investorplace.comKROS Stock Earnings: Keros Therapeutics Beats EPS for Q1 2024May 8, 2024 | globenewswire.comKeros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial ResultsMay 3, 2024 | marketbeat.comKeros Therapeutics (NASDAQ:KROS) Trading Up 7.5%Keros Therapeutics (NASDAQ:KROS) Shares Up 7.5%April 15, 2024 | marketbeat.comKeros Therapeutics, Inc. (NASDAQ:KROS) Sees Large Increase in Short InterestKeros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) was the recipient of a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 2,100,000 shares, an increase of 9.4% from the March 15th total of 1,920,000 shares. Based on an average daily volume of 413,400 shares, the days-to-cover ratio is presently 5.1 days.April 15, 2024 | finance.yahoo.comAre Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 37%?April 14, 2024 | marketbeat.comWCM Investment Management LLC Grows Stock Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS)WCM Investment Management LLC increased its stake in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 58.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 154,664 shares of the company's stock after purchasing an adApril 10, 2024 | marketbeat.comVanguard Group Inc. Increases Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS)Vanguard Group Inc. grew its stake in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 18.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,406,431 shares of the company's stoApril 6, 2024 | marketbeat.comKeros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by SG Americas Securities LLCSG Americas Securities LLC lessened its holdings in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 74.0% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 12,252 shares of the company's stock after selling 34March 29, 2024 | markets.businessinsider.comBuy Rating Affirmed for Keros Therapeutics Amid FDA Approval Landscape and Market Opportunity for KER-012March 29, 2024 | marketbeat.comQ1 2024 EPS Estimates for Keros Therapeutics, Inc. (NASDAQ:KROS) Lifted by William BlairKeros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Equities researchers at William Blair raised their Q1 2024 EPS estimates for shares of Keros Therapeutics in a research report issued to clients and investors on Wednesday, March 27th. William Blair analyst M. Phipps now anticipates that theMarch 27, 2024 | marketbeat.comKeros Therapeutics (NASDAQ:KROS) Shares Gap Down to $66.11Keros Therapeutics (NASDAQ:KROS) Shares Gap Down to $66.11March 25, 2024 | msn.comDyne Therapeutics appoints John Cox CEOMarch 22, 2024 | marketbeat.comKeros Therapeutics (NASDAQ:KROS) Trading Down 4.7%Keros Therapeutics (NASDAQ:KROS) Stock Price Down 4.7%March 19, 2024 | markets.businessinsider.comStrong Buy Rating for Keros Therapeutics Amid Favorable LR-MDS Treatment Landscape and Regulatory EnvironmentMarch 18, 2024 | marketbeat.comKeros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Rating of "Buy" by AnalystsKeros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) has received a consensus recommendation of "Buy" from the six research firms that are covering the firm, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The average twelve-month targMarch 17, 2024 | finance.yahoo.comKROS Apr 2024 30.000 putMarch 16, 2024 | finance.yahoo.comKROS Apr 2024 70.000 putMarch 16, 2024 | finance.yahoo.comKROS Apr 2024 75.000 callMarch 16, 2024 | finance.yahoo.comKROS Apr 2024 65.000 putMarch 14, 2024 | finance.yahoo.comKeros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic SyndromesMarch 5, 2024 | marketbeat.comKeros Therapeutics (NASDAQ:KROS) Shares Gap Down to $69.01Keros Therapeutics (NASDAQ:KROS) Shares Gap Down to $69.01March 5, 2024 | finance.yahoo.comKeros Therapeutics to Present at Leerink Partners 2024 Global Biopharma ConferenceMarch 4, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Purchases 29,168 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)Charles Schwab Investment Management Inc. boosted its position in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 19.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 176,953 shares of the company'March 1, 2024 | marketbeat.comKeros Therapeutics (NASDAQ:KROS) Releases Earnings Results, Beats Estimates By $0.03 EPSKeros Therapeutics (NASDAQ:KROS - Get Free Report) posted its earnings results on Friday. The company reported ($1.34) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.37) by $0.03. The business had revenue of $0.14 million for the quarter. During the same period in the previous year, the company earned ($1.09) EPS.March 1, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Keros Therapeutics (KROS), Veeva Systems (VEEV) and Capricor Therapeutics (CAPR)March 1, 2024 | marketbeat.comBraidwell LP Purchases 213,444 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)Braidwell LP raised its holdings in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 18.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,357,309 shares of the company's stock after acquiring an addiMarch 1, 2024 | marketbeat.comKeros Therapeutics, Inc. (NASDAQ:KROS) Expected to Post FY2028 Earnings of $2.27 Per ShareKeros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Leerink Partnrs upped their FY2028 earnings estimates for shares of Keros Therapeutics in a research report issued to clients and investors on Thursday, February 29th. Leerink Partnrs analyst T. Smith now expects that the company will earn $2March 1, 2024 | marketbeat.comHC Wainwright Reiterates "Buy" Rating for Keros Therapeutics (NASDAQ:KROS)HC Wainwright reiterated a "buy" rating and issued a $100.00 price objective on shares of Keros Therapeutics in a report on Friday.March 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Keros Therapeutics Amid Positive Clinical Progress and Strategic CatalystsMarch 1, 2024 | finanznachrichten.deKeros Therapeutics, Inc.: Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsFebruary 29, 2024 | markets.businessinsider.comBuy Rating Justified by Keros Therapeutics’ Clinical Advancements and Strong Financial PositionFebruary 29, 2024 | markets.businessinsider.comOptimistic Outlook for Keros Therapeutics’ Advancing Clinical Pipeline Justifies Buy RatingFebruary 29, 2024 | marketbeat.comKeros Therapeutics (KROS) Set to Announce Earnings on FridayKeros Therapeutics (NASDAQ:KROS) will be releasing earnings after the market closes on Friday, March 1, Briefing.com reports.February 28, 2024 | benzinga.comKeros Therapeutics Stock (NASDAQ:KROS), Earnings Estimates, EPS, and RevenueFebruary 28, 2024 | finance.yahoo.comKeros Therapeutics Inc (KROS) Reports Increased R&D Spending and Net Loss in 2023February 28, 2024 | globenewswire.comKeros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsFebruary 27, 2024 | marketbeat.comKeros Therapeutics (NASDAQ:KROS) Reaches New 52-Week High at $68.50Keros Therapeutics (NASDAQ:KROS) Sets New 12-Month High at $68.50February 27, 2024 | marketbeat.comFmr LLC Has $114.93 Million Position in Keros Therapeutics, Inc. (NASDAQ:KROS)Fmr LLC reduced its position in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 11.2% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 3,604,928 shares of the company's stock after selling 454,113 shares during the period. Fmr LLC owned 12.03% o Get Keros Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter. Email Address This military-backed stock “owns” AI market (Ad)The AI boom is just getting started. And the real wealth has still to be made… You must read this new presentation from Porter Stansberry. KROS Media Mentions By Week KROS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KROS News Sentiment▼0.920.76▲Average Medical News Sentiment KROS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KROS Articles This Week▼52▲KROS Articles Average Week Get Keros Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Evotec News Ardelyx News Protagonist Therapeutics News Galapagos News Syndax Pharmaceuticals News NewAmsterdam Pharma News Agios Pharmaceuticals News Catalyst Pharmaceuticals News Kura Oncology News Harmony Biosciences News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KROS) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaBiden Nomination CANCELED?The Freeport SocietyWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsThe only AI company to buyPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
